Rani Therapeutics

Yahoo Finance • 3 months ago

Rani Therapeutics stock plunges after $3 million registered direct offering

Investing.com -- Rani Therapeutics Holdings Inc (NASDAQ:RANI) stock plunged 35.8% after the clinical-stage biotherapeutics company announced a registered direct offering that will raise approximately $3 million in gross proceeds. The co... Full story

Yahoo Finance • 3 months ago

Rani Therapeutics announces $3M registered direct offering; shares down nearly 31%

* Rani Therapeutics (NASDAQ:RANI [https://seekingalpha.com/symbol/RANI]) has entered a securities purchase agreement with a single institutional investor for a $3M registered direct offering. * The deal includes the sale of .35M Class... Full story

Yahoo Finance • 3 months ago

Rani Therapeutics stock soars after announcing ENDO 2025 presentation

Investing.com -- Rani Therapeutics Holdings Inc (NASDAQ:RANI) stock surged 18% after the clinical-stage biotherapeutics company announced it will present preclinical data on its RaniPill capsule at the Endocrine Society’s Annual Meeting... Full story

Yahoo Finance • 3 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today anno... Full story

Yahoo Finance • 3 months ago

Rani Therapeutics files to sell 13.16M shares of Class A common stock by selling shareholders

* Rani Therapeutics (NASDAQ:RANI [https://seekingalpha.com/symbol/RANI]) filed a prospectus to sale 13.16 million shares of class A common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selli... Full story

Yahoo Finance • 5 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase 1 study for RT-114... Full story

Yahoo Finance • 6 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating... Full story

Yahoo Finance • 6 months ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence– - Both groups demonstrated comparable weight loss w... Full story

Yahoo Finance • 6 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ann... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results

- Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of RaniPill® HC to be Phase 1 ready - - Expansion of... Full story

Yahoo Finance • 2 years ago

The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study

– Daily administration for 60 days was well-tolerated with no treatment-related adverse events – – Preclinical data support the safety and tolerability of RaniPill® capsule for subsequent clinical studies – SAN JOSE, Calif., Oct. 25, 20... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

- RaniPill®HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – - RaniPill® HC shortlisted as a finalist b... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today anno... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

-Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate -Rani will continue preclinical testing to confirm preliminary reliability rat... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics to Participate in September Investor Conferences

SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ann... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endo... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics’ Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ann... Full story

Yahoo Finance • 3 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - - Received preliminary feedback from FDA on RT-1... Full story